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The extracellular matrix (ECM) plays a critical role in governing cell behavior and phenotype during limb 
skeletogenesis. Chondroitin sulfate proteoglycans (Cspgs) are highly expressed in the ECM of precartilage 
mesenchymal condensations and are important to limb chondrogenesis and cartilage structure, but little is 
known regarding their involvement in formation of synovial joints in the embryonic limb. Matrix versican Cspg 
expression has previously been reported in the epiphysis of developing long bones and presumptive joint; 
however, detailed analysis has not yet been conducted. In the present study we immunolocalized versican and 
aggrecan Cspgs during chick elbow joint morphogenesis between HH st25-41 of development. In this study we 
show that versican and aggrecan expression initially overlapped in the incipient cartilage model of long bones in 
the wing, but versican was also highly expressed in the perichondrium and presumptive joint interzone during 
early stages of morphogenesis (HH st25-34). By HH st36-41 versican localization was restricted to the future 
articular surfaces of the developing joint and surrounding joint capsule while aggrecan localized in an 
immediately adjacent and predominately non-overlapping region of chondrogenic cells at the epiphyses. These 
results suggest a potential role for versican proteoglycan in development and maintenance of the synovial joint 
interzone. 
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1. Introduction 
The morphogenesis of synovial joints is a 
complex and little understood process. At 
approximately HH st25 [11] of chick development the 
densely packed mesenchymal cells of the 
pre-chondrogenic Y-shaped aggregate begin to 
differentiate and give rise to chondrocytes, the 
functional unit of cartilage. Type II collagen 
immunolocalization in the newly differentiating 
Y-shaped aggregate confirms that there is 
cartilaginous continuity across the future joint location 
[4]. Shortly thereafter, the formation of a synovial joint 
at the distal end of the presumptive humerus and 
proximal ends of the presumptive radius and ulna 
separates the large aggregate into three distinct 
skeletal elements. The presumptive joint area, referred 
to as the interzone, is a three-layered structure 
consisting of a non-chondrogenic central lamina 
bordered by two chondrogenous zones from which the 
joint cavitates, thus separating the adjacent skeletal 
elements [1, 9, 20]. Interzone formation is characterized 
by appearance of a narrow band of densely packed 
flattened cells [21] that cease expression of cartilage 
specific markers such as type II collagen and aggrecan 
and begin to secrete type I collagen [4].  
Cell flattening in the interzone is not likely a 
passive process due to the growth of opposing skeletal 
elements; instead the interzone is thought to arise from 
a population of prespecified cells [13] which later 
express factors specific to the “joint” phenotype [9]. 
Secreted factors implicated in regulating interzone 
formation include Wnt14 [12], Gdf5 [26], and noggin 
[2]. In addition, the transcription factors Cux1 [18], 
ERG-3 [14] and Dlx5 and Dlx6 [8] have also been 
implicated in this process.  
Versican is a Cspg in the hyalectin family bearing 
chondroitin sulfate (CS) glycosaminoglycan (GAG) 
side chains. Versican is comprised of a core protein 
with globular domains at both N-terminal and 
C-terminal regions and central CS-attachment regions 
consisting of CS-α and CS-β domains [16, 34] and is 
predominately found in tissue with a high cell to 
matrix ratio [10, 16, 24]. The N-terminal G1 globular 
domain of versican specifically binds hyaluronan 
(HA), an interaction that is stabilized by link-protein 
(LP) [19]. Stable versican-HA-LP complexes are 
generally thought to have an anti-adhesive effect and 
create a loose, highly hydrated environment [17, 28, 
29]. These properties also suggest that versican may 
provide a mechanism to stabilize HA associated with 
cell membrane CD44: thus, forming a versican/HA 
pericellular matrix around the cell affecting adhesive 
and migratory capabilities [34]. 
Versican has previously been localized in limb 
pre-cartilage mesenchymal condensations in chick [16, 
24], at the epiphyseal ends of long bones [23, 30] and in 
the presumptive joint in mouse [25]. Ectopic versican 
expression has also been demonstrated to modulate 
chondrocyte morphology in vitro via changes in 
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cytoskeletal structure [33]; however, little else is 
known about versican’s function in this regard. 
Furthermore, the temporal and spatial expression 
pattern of versican relative to that of its close hyalectin 
family relative, aggrecan has not been examined in 
detail during synovial joint morphogenesis. The 
present study provides the first report of versican 
expression during avian elbow joint morphogenesis 
and its relationship in this region to the chondrogenic 
markers, aggrecan and type II collagen.  
2. Materials and Methods 
In order to examine the expression of versican in 
the elbow region of the developing chick limb a 
minimum of 15 normal viable embryos were evaluated 
by immunohistochemistry on paraffin embedded 
sections in order to determine the most 
consistent expression pattern for versican during 
each stage along an 11 day time-course (HH 
st25-41). Chick embryos were harvested 
following IACUC approved guidelines, placed in 
ice-cold phosphate buffered saline (PBS) and 
fixed in 4:1 methanol:dimethylsulfoxide ON at 
4oC. Fixed embryos were dehydrated through 
graded ethanols into xylene and embedded in 
paraffin. 
Primary antibodies utilized included 
polyclonal rabbit anti-chick versican and 
aggrecan [31] and monoclonal mouse anti-chick 
type II collagen antibody (II-II6B3; 
Developmental Studies Hybridoma Bank, Iowa 
City, IA). Double labeling was routinely 
performed with anti-versican in combination 
with Type II collagen antibody and in selected 
experiments with biotinylated hyaluronic acid binding 
protein (Seikagaku). 
Prior to processing for immunohistochemistry 
deparaffinized sections were incubated with 0.1% 
testicular hyaluronidase (Sigma) for 30 min at 37ºC to 
remove potentially masking GAG residues. Sections 
selected for hyaluronan localization were omitted from 
this pretreatment with the exception of samples used 
as controls to test efficacy of hyaluronidase digest. 
Subsequent immunohistochemical staining procedures 
were a modification of Capehart et al [3]. Briefly, 
sections were blocked with PBS containing 3% bovine 
serum albumin (BSA) and 1% normal goat serum 
(NGS) for 1 hr and incubated with primary 
immunoreagents overnight at 4ºC. Sections were then 
washed with PBS and incubated with fluorescein or 
rhodamine-conjugated anti-mouse or –rabbit IgG 
secondary antibodies (ICN-Cappel) diluted 1:200 in 
blocking buffer for 2 hours at room temperature. 
Sections selected for hyaluronan staining were treated 
with FITC-strepavidin (Vector Labs). Primary 
antibodies were omitted from control specimens. 
Sections were washed with PBS, post-fixed in 80% and 
50% ethanols, re-equilibriated in PBS, and mounted in 
10% PBS-90% glycerol containing 100mg/mL 
1,4-diazabicyclo(2,2,2)octane (Sigma). Slides were 
viewed with an Olympus BX-40 equipped with 
epifluorescence optics and images captured using a 
SPOT-RT camera and software. 
3. Results and Discussion 
The current study was conducted in order to 
determine if the pattern of versican expression was 
conserved and consistent with a role for this molecule 
during synovial joint development in the avian limb. 
To establish the temporal and spatial expression of 
versican and aggrecan proteoglycans relative to overt 
chondrogenesis and joint morphogenesis we 
employed immunohistochemical analysis of limb 
sections from paraffin-embedded wild-type chick 
embryos during time periods critical to elbow joint 
morphogenesis (HH st25–41).  
 
Figure 1. Immunolocalization of versican in relation to 
chondrogenic tissue in the developing chick limb. A,B are 
sections through the chick wing at HH st25, and C-F at HH st28 
of development. A,B: Versican (A) and aggrecan (B) expression 
(red) initially overlap in much of the early chondrogenic limb 
core, however, aggrecan is absent from presumptive joint 
forming regions and versican expression is also localized in the 
distal limb mesenchyme. C: Versican (green) is beginning to 
disappear from the newly differentiated humeral chondrocytes 
(asterisk), yet strong versican expression is maintained in the 
joint interzone (arrow) and perichondrium (arrowheads). D,E: 
Aggrecan (D) and type II collagen (E) expression are strongly 
localized in incipient cartilages but largely absent from the joint 
interzone (arrows). F: Phase micrograph of boxed area in panel 
C showing versican positive interzone cells. Scale bar = 250µm 
(A,B); 500µm (C,D); 500µm (E,F). 
 
Previous studies have shown that at HH st20 
versican is expressed evenly throughout the limb bud 
[24], however, by HH st25, as noted previously, 
versican expression was restricted to the chondrogenic 
mesenchyme in the older, more proximal areas (Fig. 
1A). HH st25 also marks the onset of aggrecan 
expression in the chick limb [22] and the beginnings of 
elbow joint interzone formation (Fig. 1A,B). Interzone 
formation is required for joint morphogenesis [13], and 
consistent with the cell flattening observed during this 
process, ectopic expression of a “miniversican” gene 
construct (consisting of a complete G1 domain, a 
partial CS domain, and complete G3 domain) was 
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demonstrated to promote chondrocyte elongation in 
vitro [33]. Expression of versican and aggrecan initially 
overlapped in the incipient cartilage model, however, 
aggrecan expression was reduced in the presumptive 
joint interzone and absent from the undifferentiated 
distal limb mesenchyme. At HH st28, versican 
expression began to be lost from the limb cartilage core 
(Fig. 1C,F), yet was still expressed at high levels in the 
fibroblast-like cells of the perichondrium and joint 
interzone. At this stage, aggrecan expression further 
diminished in the flattened cells of the developing joint 
(Fig. 1D) and co-distributed with the type II collagen 
positive cartilage matrix for the remaining stages 
examined (Fig. 1E).  
 Versican expression in the elbow region of HH 
st34-36 limb sections was again largely localized in 
areas where cell shape is more flattened (Fig. 2A,D). 
These areas included the epiphyseal ends of the radial, 
ulnar, and humeral cartilages and surrounding 
perichondrium. In contrast, aggrecan and Type II 
collagen expression were restricted to rounded 
chondrogenic cells of the cartilage during the 
intermediate stages of joint formation (Fig. 2B,C). The 
onset of cavitation coincides with increased 
hyaluronan synthesis and up-regulation of CD44 
expression by interzone cells [1, 5, 21]. The N-terminal 
G1 globular domain of versican specifically binds 
hyaluronan [7, 15, 19] and it is of particular interest to 
note that hyaluronan binding proteins present in the 
joint interzone have been suggested to aid in 
separation events [6]. Consistent with these findings, 
we immunolocalized strong expression of versican 
proteoglycan (Fig. 2E) and hyaluronan (Fig. 2F) in the 
joint interzone and immediate surrounding area just 
prior to cavitation. HH st36 marks onset of cavitation 
and by this stage versican expression was reduced to 
background levels in all but the epiphyseal ends of the 
cartilage template of adjacent skeletal elements 
comprising the elbow and future articular surfaces 
(Fig. 2G). At this stage, versican was also expressed by 
a population of periarticular cells at the periphery of 
the forming joint cavity.  
Articular cartilage is traditionally thought to 
simply be the remaining cartilage from the embryonic 
epiphyses that is never replaced by bone. This concept 
is, however, challenged by the hypothesis that 
articular cartilage arises from a distinct population of 
cells. Regardless of origin, permanent maintenance of 
the stable articular chondrocyte phenotype is crucial to 
joint function. By HH st38-41 cavitation of the elbow 
joint is readily evident, and although high levels of 
versican expression were found in the perichondrium 
and surrounding joint capsule, the data presented 
herein show that between HH st38-41 versican in the 
cartilaginous skeleton became more localized along the 
future articular surfaces of the radial, ulnar and 
humeral cartilages (Fig. 3A,D,F). In contrast, aggrecan 
(Fig. 3B,E) and type II collagen (Fig. 3C) were localized 
in a predominately non-overlapping region of 
underlying epiphyseal chondrogenic cells and matrix.  
These findings are in agreement with preliminary 
studies of versican localization in presumptive joint 
regions in mouse [25, 30] and further support a 
conserved role for this molecule during 
chondrogenesis and synovial joint morphogenesis in 
both avian and murine models. 
 
Figure 2: Immunolocalization of versican in relation to 
chondrogenic tissue in the developing chick limb. A-D are 
sections through the chick wing at HH st34 of development, E,F 
at HH st35 and G at HH st36 double labeled with versican 
(green) and type II collagen (red). A: Versican expression is 
reduced in the chondrogenic rod, but is maintained at high levels 
in the perichondrium (arrowheads) and joint interzone (arrows). 
B,C: Aggrecan (B) and type II collagen (C) are highly expressed 
by differentiated chondrocytes but are absent from the 
perichondrium and joint interzone (arrows). D: Phase 
micrograph of limb section in A showing cells of the joint 
interzone that express high levels of versican proteoglycan. E,F: 
Versican (E) and hyaluronan (F) expression overlap in the 
perichondrium (arrowheads) and joint interzone (arrows). 
Hyaluronan expression was widespread in limb tissues. G: 
Versican expression (green) is now largely absent from type II 
collagen (red) positive matrix, and is strongly expressed by 
periarticular cells bordering the joint space (arrows) and at the 
epiphyseal ends of the radius and ulnar olecranon process 
(arrowheads). Versican expression is also detected in the 
endomysium surrounding individual muscle fibers (+). Scale 
bars = 250µm (A-C); 250µm (D); 250µm (E,F); 250µm (G). 
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Figure 3: Immunolocalization of versican in 
relation to chondrogenic tissue in the developing 
chick limb. A,B,C are sections through the chick 
wing at HH st38 and D,E,F at HH st41 of 
development. A,D: Versican continues to localize 
along the joint interzone (arrows) and in the 
immediate surrounding area (arrowheads). Note 
progressive loss of versican in most of the maturing 
epiphysis but continued expression along articular 
surfaces of the developing elbow in D. B,C,E: As 
seen at earlier stages, strong aggrecan (B,E) and 
type II collagen (C) expression remain in all areas 
of the cartilage anlagen except for those versican 
positive regions along the developing articulation 
(small arrows). F: Phase micrograph of D, showing 
articular chondrocytes (arrows) as the likely source 
of versican expression (arrowhead denotes forming 
joint capsule). Scale bar = 250µm for all panels. 
4. Conclusion 
Development of synovial joints has 
been shown to be a complex process involving cell 
flattening, and cavitation, mediated in part by 
accumulation of hyaluronan GAG [5], all of which 
occur in the interzone. Surprisingly, despite an 
extensive number of morphological studies describing 
joint development and its clinical importance relative 
to degenerative diseases, the role many ECM 
molecules have during the growth and differentiation 
of synovial joints is far from understood.  
Extracellular matrices rich in versican and 
hyaluronan provide a highly hydrated environment 
that promotes the cell proliferation and migration, and 
the versican-HA complexes surrounding cells serve an 
important role in controlling cell shape and cell 
division [17, 27]. Furthermore, it has been 
hypothesized that versican must be downregulated 
before terminal chondrocyte differentiation can occur 
[32]. Consistent with these studies, our data show that 
versican was strongly expressed by flattened 
fibroblast-like cells of the joint interzone and 
surrounding perichondrium. This pattern of 
expression was maintained throughout the time 
period encompassing interzone formation until 
cavitation of the elbow joint. At this latter stage 
versican expression by articular chondrocytes 
continued at the epiphysis. Aggrecan on the other 
hand was shown to be exclusively localized in overt 
cartilage matrix and was absent from both the 
perichondrium and joint interzone after their first 
morphological appearance in the limb. Furthermore, 
as demonstrated here, expression of versican was in a 
largely non-overlapping pattern with aggrecan at the 
developing articulation suggesting that the cells of the 
forming articular cap possess different properties from 
the adjacent chondrocytes. This pattern of aggrecan 
localization co-distributed with type II collagen 
expression and remained constant in cartilages around 
the forming joint at all stages examined. The present 
report provides the first detailed analysis of versican 
localization during avian joint morphogenesis and 
results suggest that an ECM rich in versican may 
facilitate creation of an environment that promotes 
maintenance of the flattened fibroblast-like cell 
morphology within the interzone and may function in 
formation or organization of the articular surface. 
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